http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2121585-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bb6fb303bd7e27aeadcd95cd02dc283 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C281-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D339-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C281-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D339-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-385 |
| filingDate | 2007-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abac5c2fc9e8ed837cb623ffb98246f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69132bd6c385b448bb6432fb5afca153 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3b1de858ee726012fd1528c6346b899 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee226253e101961edde57f8f2bdc4194 |
| publicationDate | 2009-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2121585-A1 |
| titleOfInvention | Novel aminoguanidines as melanocortin receptor ligands. |
| abstract | There are described compounds of general formula (I) and isomeric forms thereof wherein n is 0,1,2 or 3, saturated or unsaturated; most preferably at least one of R<SUB>1</SUB> to R<SUB>5</SUB> represents halogen; at least one of R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>4</SUB> and R<SUB>5</SUB> is selected from -S-R or -COOR, or two or more Of R<SUB>1</SUB>-R<SUB>5</SUB> comprise a linking group such as -S-(CH2)<SUB>m</SUB>S-, where m is 1, 2 or 3 and R is selected from alkyl having 1 to 5 carbon atoms, cycloalkyl having 3-6 carbon atoms, hydroxy, and aryl having 6 to 10 carbon atoms, such groups being optionally substituted, and when R<SUB>1</SUB> is selected from -S-R, then at least one of R<SUB>2</SUB>, R<SUB>3</SUB> and R<SUB>5</SUB> is most preferably selected from halogen; and R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>4</SUB> and R<SUB>5</SUB> are otherwise the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and pharmacologically acceptable salts thereof. Compounds described have activity on the melanocortin receptors and have application in the treatment of a wide range of inflammatory, arthritic or central nerve regeneration conditions. |
| priorityDate | 2006-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 414.